California State Teachers Retirement System Reduces Position in Illumina, Inc. $ILMN

California State Teachers Retirement System lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 3.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 228,312 shares of the life sciences company's stock after selling 8,254 shares during the period. California State Teachers Retirement System owned 0.15% of Illumina worth $40,144,099 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Capital World Investors boosted its position in Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company's stock valued at $2,636,483,000 after purchasing an additional 124,323 shares during the period. BlackRock Inc. bought a new position in Illumina during the second quarter worth about $3,374,423,000. WCM Investment Management LLC grew its stake in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA bought a new stake in Illumina in the 2nd quarter valued at about $617,981,000. Finally, Geode Capital Management LLC raised its holdings in Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company's stock valued at $375,260,000 after buying an additional 130,139 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Zacks Research lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 1st. Evercore reissued an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Illumina in a research note on Monday, August 31st. Leerink Partners increased their target price on shares of Illumina from $175.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. increased their price target on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Illumina has a consensus rating of "Hold" and a consensus target price of $199.12.

Insider Transactions at Illumina

In other news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 2,062,465 shares of company stock valued at $436,589,802. Company insiders own 2.90% of the company's stock.

Illumina Stock Performance

ILMN traded up $17.99 during trading on Tuesday, hitting $226.20. The stock had a trading volume of 1,669,154 shares, compared to its average volume of 1,900,832. The company has a 50 day moving average price of $201.17 and a 200-day moving average price of $163.08. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $34.16 billion, a price-to-earnings ratio of 42.26, a P/E/G ratio of 2.93 and a beta of 1.46.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the firm posted $1.19 EPS. The business's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company's sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.